RPL9P30

Across TCGA pan-cancer cohorts, RPL9P30 RNA is linked to patient survival in 15 of 34 cancer types, making it the most broadly survival-associated RPL9P30 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher RPL9P30 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPL9P30 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CESC show a favorable association.

LIHC, HNSC, and MESO are the cancer types where RPL9P30 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Tertile	All	0.228	0.477	<.001	90	view →
HNSC	OS	Quartile	III,IV	0.584	0.323	.005	50	view →
MESO	OS	Tertile	IV	0.152	0.708	<.001	45	view →
CESC	OS	Tertile	All	0.790	0.435	<.001	38	view →
KIRC	DFS	Tertile	All	0.753	0.823	.007	29	view →
DLBC	OS	Tertile	II,III,IV	0.725	1.000	.011	29	view →
UVM	DFS	Tertile	III,IV	0.075	0.682	<.001	27	view →
SKCM	OS	Tertile	All	0.844	0.765	.013	18	view →
ACC	DFS	Tertile	All	1.000	0.346	.015	18	view →
COAD	DFS	Tertile	II,III,IV	0.334	0.534	.024	12	view →
PCPG	OS	Tertile	All	0.792	0.958	.026	9	view →
ESCA	DFS	Quartile	All	0.277	0.504	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 15 lineages.

RPL9P30–LIHC (DFS)

Open the LIHC breakdown →